Avalyn Pharma Inc. Deferred Offering Costs
Avalyn Pharma Inc. (AVLN) had Deferred Offering Costs of $200.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-12
- 2026-06-30: Deferred Offering Costs $200.00K.
- 2026-03-31: Deferred Offering Costs $2.70M.
- 2025-12-31: Deferred Offering Costs $300.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $2.70M 10-Q · filed 2026-06-03 |
| 2025-12-31 | $300.00K 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |